Unicycive Therapeutics Future Growth
Future criteria checks 3/6
Unicycive Therapeutics is forecast to grow earnings and revenue by 50.4% and 49.7% per annum respectively while EPS is expected to grow by 55.1% per annum.
Key information
50.4%
Earnings growth rate
55.1%
EPS growth rate
| Biotechs earnings growth | 23.7% |
| Revenue growth rate | 49.7% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Apr 2024 |
Recent future growth updates
Recent updates
Will Unicycive Therapeutics (NASDAQ:UNCY) Spend Its Cash Wisely?
Feb 16
We're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Rate
Aug 18Unicycive Therapeutics (NASDAQ:UNCY) Will Have To Spend Its Cash Wisely
Mar 08Unicycive stock soars 25% as kidney drug UNI-494 shows promise in preclinical study in rats
Sep 07Unicycive Therapeutics GAAP EPS of -$0.24
Aug 16Unicycive inks licensing deal for kidney disease drug Renazorb in Asia
Jul 18Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 248 | 104 | 67 | 150 | 4 |
| 12/31/2025 | 24 | -28 | -42 | 1 | 5 |
| 12/31/2024 | N/A | -26 | -52 | -23 | 4 |
| 12/31/2023 | 1 | -31 | -18 | -18 | N/A |
| 9/30/2023 | 1 | -29 | -20 | -20 | N/A |
| 6/30/2023 | 2 | -30 | -19 | -19 | N/A |
| 3/31/2023 | 2 | -29 | -17 | -17 | N/A |
| 12/31/2022 | 1 | -18 | -16 | -16 | N/A |
| 9/30/2022 | 1 | -15 | -11 | -11 | N/A |
| 6/30/2022 | N/A | -15 | -11 | -11 | N/A |
| 3/31/2022 | N/A | -13 | -8 | -8 | N/A |
| 12/31/2021 | N/A | -10 | -6 | -6 | N/A |
| 9/30/2021 | N/A | -8 | -5 | -5 | N/A |
| 6/30/2021 | N/A | -4 | -2 | -2 | N/A |
| 3/31/2021 | N/A | -3 | -2 | -2 | N/A |
| 12/31/2020 | N/A | -2 | -1 | -1 | N/A |
| 9/30/2020 | N/A | -2 | -1 | -1 | N/A |
| 6/30/2020 | N/A | -2 | -1 | -1 | N/A |
| 3/31/2020 | N/A | -2 | -1 | -1 | N/A |
| 12/31/2019 | N/A | -2 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: UNCY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: UNCY is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: UNCY is expected to become profitable in the next 3 years.
Revenue vs Market: UNCY is forecast to have no revenue next year.
High Growth Revenue: UNCY is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if UNCY's Return on Equity is forecast to be high in 3 years time